Work

Poster: CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial

Year: 2022

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)00882-5

Authors: Timothy P. Hughes, Jorge E. Cortes, Delphine Réa, Michael J. Mauro, Andreas Hochhaus, Dong-Wook Kim, Koji Sasaki, Fabian Lang, Michael C. Heinrich, Massimo Breccia, Michael Deininger, Yeow-Tee Goh, Jeroen J.W.M Janssen, Moshe Talpaz, Philipp le Coutre, Shruti Kapoor, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Francois-Xavier Mahon

Institutions: South Australian Health and Medical Research Institute, The University of Adelaide

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296532650

FWCI: 0.312

Cites:

Cited by: 2

Related to: 10